Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor

Table 1 Macroscopic evaluation of gastric mucosa

Groups	n	Weight (gr)	GML count	GML area mm2
Sham	8	223.50 ± 18.40 (200-249)	0	0
Indomethacin	8	225.00 ± 13.77 (201-248)	6.25 ± 3.49 (1-11)a	21.00 ± 12.35 (1-36)b
Famotidine 5 (F5)	8	223.25 ± 13.13 (203-236)	4.12 ± 2.47 (2-8)	8.62 ± 2.97 (3-12)
Famotidine 20 (F20)	8	224.75 ± 14.78 (200-247)	2.37 ± 4.43 (0-13)	0.94 ± 2,06 (0-6)d
Vardenafil 2 (V2)	8	221.12 ± 13.27 (204-242)	4.37 ± 3.06 (0-8)	6.62 ± 5.87 (0-16)e
Vardenafil 10 (V10)	8	224.12 ± 15.16 (202-250)	1.25 ± 1.38 (0-3)cg	0.75 ± 0.88 (0-2)dg

GML: Gastric mucosal lesion. The values are presented as mean ± SD, (min-max).

^aP < 0.05,

^bP < 0.001 vs all other groups;

^cP < 0.05,

^dP < 0.001 vs group F5;

^eP < 0.05 vs group F20;

^gP < 0.05 vs group V2.